Raymond James analyst Danielle Brill resumed coverage of Regenxbio with an Outperform rating and $45 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGNX:
